India · Delayed Price · Currency is INR Vivo Bio Tech Statistics
Total Valuation
Vivo Bio Tech has a market cap or net worth of INR 328.64 million. The enterprise value is 988.09 million.
| Market Cap | 328.64M |
| Enterprise Value | 988.09M |
Important Dates
The next confirmed earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivo Bio Tech has 22.19 million shares outstanding. The number of shares has increased by 38.35% in one year.
| Current Share Class | 22.19M |
| Shares Outstanding | 22.19M |
| Shares Change (YoY) | +38.35% |
| Shares Change (QoQ) | +14.46% |
| Owned by Insiders (%) | 11.09% |
| Owned by Institutions (%) | n/a |
| Float | 8.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 0.94 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.79 |
| EV / EBITDA | 4.69 |
| EV / EBIT | 10.40 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.94 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 3.20 |
| Debt / FCF | n/a |
| Interest Coverage | 1.70 |
Financial Efficiency
Return on equity (ROE) is -2.00% and return on invested capital (ROIC) is -4.65%.
| Return on Equity (ROE) | -2.00% |
| Return on Assets (ROA) | 4.21% |
| Return on Invested Capital (ROIC) | -4.65% |
| Return on Capital Employed (ROCE) | 7.30% |
| Weighted Average Cost of Capital (WACC) | -2.22% |
| Revenue Per Employee | 2.23M |
| Profits Per Employee | -115,721 |
| Employee Count | 247 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.06 |
Taxes
In the past 12 months, Vivo Bio Tech has paid 65.27 million in taxes.
| Income Tax | 65.27M |
| Effective Tax Rate | 177.91% |
Stock Price Statistics
The stock price has decreased by -55.82% in the last 52 weeks. The beta is 0.40, so Vivo Bio Tech's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -55.82% |
| 50-Day Moving Average | 15.73 |
| 200-Day Moving Average | 22.74 |
| Relative Strength Index (RSI) | 51.51 |
| Average Volume (20 Days) | 7,026 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vivo Bio Tech had revenue of INR 551.03 million and -28.58 million in losses. Loss per share was -1.29.
| Revenue | 551.03M |
| Gross Profit | 466.26M |
| Operating Income | 94.98M |
| Pretax Income | 36.69M |
| Net Income | -28.58M |
| EBITDA | 210.49M |
| EBIT | 94.98M |
| Loss Per Share | -1.29 |
Balance Sheet
The company has 14.36 million in cash and 673.81 million in debt, with a net cash position of -659.45 million or -29.72 per share.
| Cash & Cash Equivalents | 14.36M |
| Total Debt | 673.81M |
| Net Cash | -659.45M |
| Net Cash Per Share | -29.72 |
| Equity (Book Value) | 931.58M |
| Book Value Per Share | 45.47 |
| Working Capital | -18.16M |
Cash Flow
In the last 12 months, operating cash flow was 349.31 million and capital expenditures -374.38 million, giving a free cash flow of -25.07 million.
| Operating Cash Flow | 349.31M |
| Capital Expenditures | -374.38M |
| Depreciation & Amortization | 115.51M |
| Net Borrowing | 116.72M |
| Free Cash Flow | -25.07M |
| FCF Per Share | -1.13 |
Margins
Gross margin is 84.62%, with operating and profit margins of 17.24% and -5.19%.
| Gross Margin | 84.62% |
| Operating Margin | 17.24% |
| Pretax Margin | 6.66% |
| Profit Margin | -5.19% |
| EBITDA Margin | 38.20% |
| EBIT Margin | 17.24% |
| FCF Margin | n/a |
Dividends & Yields
Vivo Bio Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.35% |
| Shareholder Yield | -38.35% |
| Earnings Yield | -8.70% |
| FCF Yield | -7.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 7, 2005. It was a reverse split with a ratio of 0.1.
| Last Split Date | Oct 7, 2005 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |